External Content

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

(Bloomberg) -- Novartis AG said an experimental drug for acute heart failure didn’t meet the goals in a late-stage clinical trial, dashing the hopes for a medicine once seen by the company as having the potential for annual sales of $1 billion.

The compound, serelaxin, didn’t lower cardiovascular deaths or reduce worsening heart failure as expected in the RELAX-AHF-2 trial, the Basel, Switzerland-based company said in a a statement Wednesday. Novartis will further analyze the results to evaluate the next steps for the drug’s development, according to the statement.

Novartis had hoped that the trial would provide evidence to win over regulators in the U.S. and the European Union who had refused to approve the drug. The Food and Drug Administration in 2014 asked for more information about serelaxin after staff members found insufficient evidence that serelaxin would benefit patients. The EU regulator also questioned the efficacy of the medicine and cited concerns about how a previous trial was run.

Analysts predict the drug will have annual sales of $359 million by 2020, based on the average of 11 estimates.

To contact the reporter on this story: Phil Serafino in Paris at pserafino@bloomberg.net.

To contact the editors responsible for this story: Benedikt Kammel at bkammel@bloomberg.net, Anjali Cordeiro

©2017 Bloomberg L.P.

Neuer Inhalt

Horizontal Line


subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.







Click here to see more newsletters

swissinfo EN

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

Join us on Facebook!

Bloomberg